Skip to content

Author

Wen-Ming Chen

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Relapse patterns and clinical outcomes after BCMA-directed CAR-T therapy in multiple myeloma: a real-world single-center study

Despite deep remissions achieved with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (MM), most patients eventually relapse. Although extramedullary disease (EMD) has been associated with poor prognosis after BCMA-directed CAR-T the...

Qi-Ling Bu, Yi-Wen Jiang, Hui-Xing Zhou et al. · 0 citations
Open access Oct 2026

Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China.

Aim: Expanding treatment options for transplant-ineligible newly diagnosed multiple myeloma (ndMM) in China has increased the need to identify treatment strategies that improve patient outcomes while using healthcare resources efficiently. This study evaluated the cost-effectiveness of in-class transition (iCT) to ixaz...

Gen-Yong Zuo, Ai-Jun Liu, Zun-Min Zhu et al. · 0 citations
Clinical trial Oct 2026

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.

BACKGROUND Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies, particularly in patients with relapsed or refractory multiple myeloma with 1q21+. We aimed to evaluate fe...

Hai-Yan He, J. Shang, Ya-Fei Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.